{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:07:34Z","timestamp":1788883654097,"version":"build-2803163510"},"reference-count":135,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Reg Anesth Pain Med"],"accepted":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Intrathecal drug delivery (IDD) is an established therapy for patients with refractory pain across cancer and non-cancer populations. By enabling targeted spinal drug delivery, IDD can provide durable symptom control at substantially lower doses than systemic therapy, often reducing systemic medication burden and treatment-limiting adverse effects. Despite decades of clinical experience and supportive evidence, IDD remains underutilized and largely concentrated in high-volume centers, reflecting persistent uncertainty related to patient selection, trialing, device planning, long-term management, limited evidence, and complication mitigation.<\/jats:p>\n                  <jats:p>This practical guide synthesizes current evidence, consensus recommendations, and collective international clinical experience to provide a structured approach to short-term and long-term management of implantable IDD systems. Shared principles applicable across indications are emphasized, while cancer-specific considerations are addressed separately, including prognosis, coordination with oncologic therapies, evolving spinal anatomy, and compressed treatment horizons. Key topics include preimplant evaluation and risk mitigation, trialing strategies and their limitations, pump and catheter selection, perioperative management, early post-implant troubleshooting, long-term maintenance, and surveillance for device-related, biological, and operational complications. Intrathecal pharmacologic strategies for pain are examined, including opioids, local anesthetics, ziconotide, clonidine, and baclofen, with attention to indication-specific dosing, titration, and safety considerations.<\/jats:p>\n                  <jats:p>Clinical outcomes are framed beyond pain intensity alone, emphasizing functional improvement, quality of life, and reduction in systemic medication use as clinically meaningful endpoints. Differences in therapeutic goals, time horizons, and risk tolerance between cancer and non-cancer populations are integrated into a practical decision framework aligned with real-world pain practice. International and regional practice variations are also discussed to contextualize differences in drug availability, compounding practices, and reimbursement. By consolidating pragmatic guidance across the full lifecycle of intrathecal therapy, this guide aims to support consistent, safe, and effective use of IDD for complex pain management in contemporary practice.<\/jats:p>","DOI":"10.1136\/rapm-2025-107404","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:23:17Z","timestamp":1788880997000},"page":"1065-1087","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Practical guide to intrathecal drug delivery: short-term and long-term management and complications"],"prefix":"10.1136","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3419-9209","authenticated-orcid":false,"given":"Eellan","family":"Sivanesan","sequence":"first","affiliation":[{"name":"Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Bienfait","sequence":"additional","affiliation":[{"name":"Anesthesiology and Pain Department, Institut de Canc\u00e9rologie de l\u2019Ouest, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5971-9111","authenticated-orcid":false,"given":"Yian","family":"Chen","sequence":"additional","affiliation":[{"name":"Anesthesiology, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1777-2130","authenticated-orcid":false,"given":"Denis","family":"Dupoiron","sequence":"additional","affiliation":[{"name":"Anesthesia and Pain Medicine, Institut de Cancerologie de l\u2019Ouest Site Paul Papin, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W","family":"Odell","sequence":"additional","affiliation":[{"name":"Anesthesiology, University of Utah Health, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-1296","authenticated-orcid":false,"given":"Christophe","family":"Perruchoud","sequence":"additional","affiliation":[{"name":"Clinique de la douleur, La Tour Medical Group, Meyrin, Switzerland"},{"name":"Service d\u2019anesth\u00e9siologie, CHUV, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-6803","authenticated-orcid":false,"given":"Jill E","family":"Sindt","sequence":"additional","affiliation":[{"name":"Anesthesiology, University of Utah Health, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-1742","authenticated-orcid":false,"given":"Shane E","family":"Brogan","sequence":"additional","affiliation":[{"name":"Anesthesiology, University of Utah Health, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026090808100904000_51.9.1065.1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00006254-198204000-00023","article-title":"Continuous Low-dose Intrathecal Morphine Administration in the Treatment of Chronic Pain of Malignant Origin","volume":"37","author":"Onofrio","year":"1982","journal-title":"Obstet Gynecol Surv"},{"key":"2026090808100904000_51.9.1065.2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(89)90020-1"},{"key":"2026090808100904000_51.9.1065.3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3171\/jns.1982.57.3.0360","article-title":"Benefit from and tolerance to continuous intrathecal infusion of morphine for intractable cancer pain","volume":"57","author":"Greenberg","year":"1982","journal-title":"J Neurosurg"},{"key":"2026090808100904000_51.9.1065.4","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1986.64.6.0890"},{"key":"2026090808100904000_51.9.1065.5","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1987.67.2.0182"},{"key":"2026090808100904000_51.9.1065.6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3171\/jns.1987.66.2.0181","article-title":"Long-term intrathecal baclofen infusion for treatment of spasticity","volume":"66","author":"Penn","year":"1987","journal-title":"J Neurosurg"},{"key":"2026090808100904000_51.9.1065.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.118"},{"key":"2026090808100904000_51.9.1065.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2005.10.003"},{"key":"2026090808100904000_51.9.1065.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.1.63"},{"key":"2026090808100904000_51.9.1065.10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.neurom.2024.08.006","article-title":"The Polyanalgesic Consensus Conference (PACC)\u00ae: Updates on Clinical Pharmacology and Comorbidity Management in Intrathecal Drug Delivery for Cancer Pain","volume":"28","author":"Deer","year":"2025","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.11","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.neurom.2023.05.001","article-title":"Intrathecal Drug Delivery Systems for Cancer Pain Control: Insights on Current Contemporary Practices in the US","volume":"26","author":"Goel","year":"2023","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1213\/ANE.0000000000004425","article-title":"Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry","volume":"130","author":"Stearns","year":"2020","journal-title":"Anesthesia & Analgesia"},{"key":"2026090808100904000_51.9.1065.13","doi-asserted-by":"crossref","DOI":"10.3389\/fpain.2025.1481245","article-title":"Underutilized treatments for patients with refractory cancer pain: a qualitative study assessing the use of intrathecal drug delivery devices in the United Kingdom compared to alternative treatments in cancer pain management","volume":"6","author":"Barnosky","year":"2025","journal-title":"Front Pain Res (Lausanne)"},{"key":"2026090808100904000_51.9.1065.14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/ner.13264","article-title":"The Unmet Need for Intrathecal Drug Delivery Pumps for the Treatment of Cancer Pain in England: An Assessment of the Hospital Episode Statistics Database","volume":"23","author":"Duarte","year":"2020","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.15","doi-asserted-by":"crossref","DOI":"10.3389\/fpain.2022.900566","article-title":"Intrathecal Drug Delivery: Advances and Applications in the Management of Chronic Pain Patient","volume":"3","author":"De Andres","year":"2022","journal-title":"Front Pain Res (Lausanne)"},{"key":"2026090808100904000_51.9.1065.16","doi-asserted-by":"crossref","unstructured":"Banik RK , Ko JS , Jiminez F , et al . Lost in conversion: navigating the challenges of converting intrathecal opioids to oral equivalents\u2014a case report and literature review. Reg Anesth Pain Med 2025. doi:10.1136\/rapm-2025-106550. [Epub ahead of print: 3 July 2025].","DOI":"10.1136\/rapm-2025-106550"},{"key":"2026090808100904000_51.9.1065.17","doi-asserted-by":"publisher","DOI":"10.1097\/AAP.0000000000000251"},{"key":"2026090808100904000_51.9.1065.18","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1526-4637.2010.00876.x","article-title":"Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up","volume":"11","author":"Atli","year":"2010","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.19","doi-asserted-by":"publisher","DOI":"10.1111\/ner.13053"},{"key":"2026090808100904000_51.9.1065.20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/ner.13175","article-title":"Initiation of Intrathecal Drug Delivery Dramatically Reduces Systemic Opioid Use in Patients With Advanced Cancer","volume":"23","author":"Sindt","year":"2020","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.21","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200406000-00034"},{"key":"2026090808100904000_51.9.1065.22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/ner.12579","article-title":"The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/ner.12565","article-title":"The Neurostimulation Appropriateness Consensus Committee (NACC) Recommendations for Infection Prevention and Management","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.24","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.surg.2023.02.017","article-title":"The implications of vaping on surgical wound healing: A systematic review","volume":"173","author":"Ashour","year":"2023","journal-title":"Surgery"},{"key":"2026090808100904000_51.9.1065.25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/ans.70130","article-title":"Vaping and surgery: what do we know?","volume":"95","author":"Jacobsen","year":"2025","journal-title":"ANZ J Surg"},{"key":"2026090808100904000_51.9.1065.26","doi-asserted-by":"publisher","DOI":"10.1097\/AAP.0000000000000700"},{"key":"2026090808100904000_51.9.1065.27","doi-asserted-by":"crossref","first-page":"100446","DOI":"10.1016\/j.jbo.2022.100446","article-title":"Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review","volume":"35","author":"Van den Brande","year":"2022","journal-title":"J Bone Oncol"},{"key":"2026090808100904000_51.9.1065.28","doi-asserted-by":"crossref","DOI":"10.3389\/fradi.2022.962797","article-title":"Imaging of metastatic epidural spinal cord compression","volume":"2","author":"Bai","year":"2022","journal-title":"Front Radiol"},{"key":"2026090808100904000_51.9.1065.29","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0909-3"},{"key":"2026090808100904000_51.9.1065.30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1213\/ANE.0000000000004639","article-title":"The Rate of Infectious Complications After Intrathecal Drug Delivery System Implant for Cancer-Related Pain Is Low Despite Frequent Concurrent Anticancer Treatment or Leukopenia","volume":"131","author":"Sindt","year":"2020","journal-title":"Anesth Analg"},{"key":"2026090808100904000_51.9.1065.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026090808100904000_51.9.1065.32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/ALN.0000000000004669","article-title":"Antiplatelet and Wound Healing Implications of Immunotherapy and Targeted Cancer Therapies in the Perioperative Period","volume":"139","author":"Sindt","year":"2023","journal-title":"Anesthesiology"},{"key":"2026090808100904000_51.9.1065.33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pme.12037","article-title":"Implanted intrathecal drug delivery systems and radiation treatment","volume":"14","author":"Gebhardt","year":"2013","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.34","doi-asserted-by":"publisher","DOI":"10.1111\/ner.13372"},{"key":"2026090808100904000_51.9.1065.35","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji005"},{"key":"2026090808100904000_51.9.1065.36","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111761","article-title":"ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1\/TRK\/ALK Inhibitor Repotrectinib, While OATP1A\/1B, ABCG2, and CYP3A Limit Its Oral Availability","volume":"13","author":"Li","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026090808100904000_51.9.1065.37","article-title":"Care for patients with cancer and substance use disorders: a qualitative study of oncology team experiences","volume":"33","author":"Kale","year":"2025","journal-title":"Support Care Cancer"},{"key":"2026090808100904000_51.9.1065.38","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1016\/j.jpainsymman.2021.05.002","article-title":"Compassion Inequities and Opioid Use Disorder: A Matched Case-Control Analysis Examining Inpatient Management of Cancer-Related Pain for Patients With Opioid Use Disorder","volume":"62","author":"Singh","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"2026090808100904000_51.9.1065.39","doi-asserted-by":"crossref","DOI":"10.1007\/s11916-025-01409-9","article-title":"Trialing Strategies Prior to Intrathecal Drug Delivery in Cancer-Related Pain: A Narrative Review","volume":"29","author":"Roux","year":"2025","journal-title":"Curr Pain Headache Rep"},{"key":"2026090808100904000_51.9.1065.40","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(95)00099-2"},{"key":"2026090808100904000_51.9.1065.41","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.neurom.2024.03.003","article-title":"The Polyanalgesic Consensus Conference (PACC)\u00ae: Intrathecal Drug Delivery Guidance on Safety and Therapy Optimization When Treating Chronic Noncancer Pain","volume":"27","author":"Deer","year":"2024","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1526-4637.2004.04011.x","article-title":"Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain","volume":"5","author":"Deer","year":"2004","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/ner.12342","article-title":"A Prospective, Randomized, Single-Blinded, Head-to-Head Long-Term Outcome Study, Comparing Intrathecal (IT) Boluses With Continuous Infusion Trialing Techniques Prior to Implantation of Drug Delivery Systems (DDS) for the Treatment of Severe Intractable Chronic Nonmalignant Pain","volume":"18","author":"Hamza","year":"2015","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/ner.12543","article-title":"The Polyanalgesic Consensus Conference (PACC): Recommendations for Trialing of Intrathecal Drug Delivery Infusion Therapy","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.45","doi-asserted-by":"crossref","DOI":"10.1177\/20494637241280356","article-title":"Intrathecal drug delivery for the management of pain and spasticity in adults: British Pain Society\u2019s recommendations for best clinical practice","volume":"2024","author":"Eldabe","year":"2024","journal-title":"Br J Pain"},{"key":"2026090808100904000_51.9.1065.46","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2022-103770"},{"key":"2026090808100904000_51.9.1065.47","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1213\/ANE.0000000000004276","article-title":"Prospective Association of Serum Opioid Levels and Clinical Outcomes in Patients With Cancer Pain Treated With Intrathecal Opioid Therapy","volume":"130","author":"Brogan","year":"2020","journal-title":"Anesth Analg"},{"key":"2026090808100904000_51.9.1065.48","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1213\/ANE.0000000000002903","article-title":"Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year Period in a Comprehensive Cancer Center","volume":"126","author":"Carvajal","year":"2018","journal-title":"Anesth Analg"},{"key":"2026090808100904000_51.9.1065.49","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2023-104961"},{"key":"2026090808100904000_51.9.1065.50","unstructured":"Medtronic . Product surveillance registry (psr) database. Minneapolis, mn; 2015."},{"key":"2026090808100904000_51.9.1065.51","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200607000-00027"},{"key":"2026090808100904000_51.9.1065.52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00006123-199308000-00007","article-title":"The distribution of medication along the spinal canal after chronic intrathecal administration","volume":"33","author":"Kroin","year":"1993","journal-title":"Neurosurgery"},{"key":"2026090808100904000_51.9.1065.53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2009.01989.x"},{"key":"2026090808100904000_51.9.1065.54","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.neurom.2025.05.007","article-title":"High Cervical Intrathecal Targeted Drug Delivery for Refractory Neuropathic Craniofacial Pain","volume":"28","author":"Desai","year":"2025","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.55","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/pm\/pnac195","article-title":"Efficacy of Continuous Intrathecal Infusion Trialing with a Mixture of Fentanyl and Bupivacaine in Chronic Low Back Pain Patients","volume":"24","author":"Hayek","year":"2023","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.56","doi-asserted-by":"publisher","DOI":"10.1111\/ner.12003"},{"key":"2026090808100904000_51.9.1065.57","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ner.12293","article-title":"Ziconotide Trialing by Intrathecal Bolus Injections: An Open-Label Non-Randomized Clinical Trial in Postoperative\/Posttraumatic Neuropathic Pain Patients Refractory to Conventional Treatment","volume":"18","author":"B\u00e4ckryd","year":"2015","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.36076\/ppj.2011\/14\/343","article-title":"Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain","volume":"14","author":"Grider","year":"2011","journal-title":"Pain Physician"},{"key":"2026090808100904000_51.9.1065.59","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.chest.2018.07.019","article-title":"Sleep Disturbance and Pain: A Tale of Two Common Problems","volume":"154","author":"Andersen","year":"2018","journal-title":"Chest"},{"key":"2026090808100904000_51.9.1065.60","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/ner.12469","article-title":"Upper Antero-Medial Thigh as an Alternative Site for Implantation of Intrathecal Pumps: A Case Series","volume":"19","author":"Narang","year":"2016","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.61","doi-asserted-by":"crossref","DOI":"10.1213\/XAA.0000000000001464","article-title":"Alternative Implantation Site of Intrathecal Pump in the Submuscular Plane of the Pectoralis Major Muscle: A Case Report","volume":"15","author":"Patel","year":"2021","journal-title":"A&A Practice"},{"key":"2026090808100904000_51.9.1065.62","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ner.12538","article-title":"The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.63","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200003000-00018"},{"key":"2026090808100904000_51.9.1065.64","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181c38da5"},{"key":"2026090808100904000_51.9.1065.65","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200012000-00037"},{"key":"2026090808100904000_51.9.1065.66","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(10)60354-6","article-title":"Ziconotide for treatment of severe chronic pain","volume":"375","author":"Schmidtko","year":"2010","journal-title":"The Lancet"},{"key":"2026090808100904000_51.9.1065.67","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e3182536211"},{"key":"2026090808100904000_51.9.1065.68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/AAP.0b013e3181fe7f29","article-title":"Measured density and calculated baricity of custom-compounded drugs for chronic intrathecal infusion","volume":"36","author":"Hejtmanek","year":"2011","journal-title":"Reg Anesth Pain Med"},{"key":"2026090808100904000_51.9.1065.69","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/pm\/pnw229","article-title":"Comparison of the Effects of Intermittent Boluses to Simple Continuous Infusion on Patients\u2019 Global Perceived Effect in Intrathecal Therapy for Pain: A Randomized Double-Blind Crossover Study","volume":"18","author":"Eldabe","year":"2017","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.70","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1526-4637.2011.01188.x","article-title":"Age-dependent intrathecal opioid escalation in chronic noncancer pain patients","volume":"12","author":"Hayek","year":"2011","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.71","doi-asserted-by":"crossref","first-page":"105597","DOI":"10.1016\/j.clineuro.2019.105597","article-title":"Cerebrospinal fluid opening pressure: The effect of body mass index and body composition","volume":"188","author":"Wakerley","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"2026090808100904000_51.9.1065.72","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.neurom.2022.02.230","article-title":"Dorsal Versus Ventral Intrathecal Catheter Tip Location and Effect on Dose Escalation and Opioid Use in Patients With Cancer Pain","volume":"26","author":"Brogan","year":"2023","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.73","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jclinane.2018.10.020","article-title":"Retrograde placement of an intrathecal catheter for chronic low pelvic cancer pain","volume":"54","author":"Urits","year":"2019","journal-title":"J Clin Anesth"},{"key":"2026090808100904000_51.9.1065.74","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/ner.13161","article-title":"Evaluation of Fixed Intrathecal Bupivacaine Infusion Doses in the Oncologic Population","volume":"23","author":"Chen","year":"2020","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.75","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2189588","article-title":"Gadolinium-based MR cisternography with prepontine cisternal routine for evaluating distribution pattern of intrathecal targeted drug delivery in pain management","volume":"30","author":"Zhou","year":"2023","journal-title":"Drug Deliv"},{"key":"2026090808100904000_51.9.1065.76","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/ner.13517","article-title":"Initial Intrathecal Dose Titration and Predictors of Early Dose Escalation in Patients With Cancer Using a 100:1 Oral to Intrathecal Morphine Conversion Ratio","volume":"24","author":"Sindt","year":"2021","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.77","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/j.1526-4637.2011.01262.x","article-title":"Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary","volume":"12","author":"Brogan","year":"2011","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1526-4637.2010.00889.x","article-title":"Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain","volume":"11","author":"Coffey","year":"2010","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.79","doi-asserted-by":"publisher","DOI":"10.1111\/ner.13325"},{"key":"2026090808100904000_51.9.1065.80","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1526-4637.2012.01451.x","article-title":"Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain","volume":"13","author":"Hamza","year":"2012","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.81","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2014.01.304","article-title":"(393) Effect of concomitant antidepressant and anticonvulsant use on adverse events in patients receiving intrathecal ziconotide in a long-term extension study","volume":"15","author":"Wallace","year":"2014","journal-title":"J Pain"},{"key":"2026090808100904000_51.9.1065.82","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(96)00010-3"},{"key":"2026090808100904000_51.9.1065.83","doi-asserted-by":"crossref","first-page":"395","DOI":"10.36076\/ppj.2012\/15\/395","article-title":"Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol","volume":"15","author":"Dupoiron","year":"2012","journal-title":"Pain Physician"},{"key":"2026090808100904000_51.9.1065.84","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/j.1526-4637.2011.01232.x","article-title":"Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients","volume":"12","author":"Veizi","year":"2011","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.85","unstructured":"Targeted drug delivery systems 2024 medtronic product performance report executive summary. Available: https:\/\/www.medtronic.com\/content\/dam\/medtronic-wide\/public\/united-states\/products\/neurological\/product-performance-report-targeted-drug-delivery.pdf [Accessed 8 Nov 2025]."},{"key":"2026090808100904000_51.9.1065.86","article-title":"Treatment of Refractory Postdural Puncture Headache after Intrathecal Drug Delivery System Implantation with Epidural Blood Patch Procedures: A 20-Year Experience","volume":"2016","author":"Bendel","year":"2016","journal-title":"Pain Res Treat"},{"key":"2026090808100904000_51.9.1065.87","article-title":"Management of Cerebrospinal Fluid Leak After Intrathecal Baclofen Pump Procedures in Adolescents With Cerebral Palsy: A Retrospective Study","volume":"16","author":"Brenn","year":"2024","journal-title":"Cureus"},{"key":"2026090808100904000_51.9.1065.88","first-page":"E211","article-title":"Preventing Post Dural Puncture Headache after Intrathecal Drug Delivery System Implantation Through Preventive Fibrin Glue Application: A Retrospective Study","volume":"24","author":"Dupoiron","year":"2021","journal-title":"Pain Physician"},{"key":"2026090808100904000_51.9.1065.89","doi-asserted-by":"publisher","DOI":"10.1053\/eujp.2000.0199"},{"key":"2026090808100904000_51.9.1065.90","doi-asserted-by":"crossref","first-page":"363","DOI":"10.36076\/ppj.2012\/15\/363","article-title":"A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain","volume":"15","author":"Duarte","year":"2012","journal-title":"Pain Physician"},{"key":"2026090808100904000_51.9.1065.91","article-title":"Refilling Intrathecal Drug Delivery Pumps Outside the Clinic: Survey of Practice in the United Kingdom","volume":"14","author":"Kirker","year":"2025","journal-title":"Adv Rehabil Sci Pract"},{"key":"2026090808100904000_51.9.1065.92","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10225353","article-title":"Hospital at Home for Intrathecal Pump Refills: A Prospective Effectiveness, Safety and Feasibility Study","volume":"10","author":"Goudman","year":"2021","journal-title":"J Clin Med"},{"key":"2026090808100904000_51.9.1065.93","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.neurom.2021.10.002","article-title":"Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration","volume":"26","author":"Robert","year":"2023","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.94","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1525-1403.2007.00130.x","article-title":"Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration","volume":"10 Suppl 1","author":"Shields","year":"2007","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.95","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1403.2005.00034.x"},{"key":"2026090808100904000_51.9.1065.96","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.neurom.2023.11.009","article-title":"Physicochemical Stability Study of the Morphine-Bupivacaine-Ziconotide Association","volume":"27","author":"Sorrieul","year":"2024","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1403.2012.00479.x"},{"key":"2026090808100904000_51.9.1065.98","doi-asserted-by":"crossref","DOI":"10.1097\/PR9.0000000000001066","article-title":"Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank","volume":"8","author":"Baskozos","year":"2023","journal-title":"Pain Rep"},{"key":"2026090808100904000_51.9.1065.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.10.028"},{"key":"2026090808100904000_51.9.1065.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.10.002"},{"key":"2026090808100904000_51.9.1065.101","doi-asserted-by":"publisher","DOI":"10.1046\/j.1533-2500.2002.02040.x"},{"key":"2026090808100904000_51.9.1065.102","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae135"},{"key":"2026090808100904000_51.9.1065.103","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac158"},{"key":"2026090808100904000_51.9.1065.104","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2011.12.007"},{"key":"2026090808100904000_51.9.1065.105","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/pm\/pnw203","article-title":"Surgical Site Infections in Cancer Patients with Intrathecal Drug Delivery Devices","volume":"18","author":"Scanlon","year":"2017","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.106","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0009"},{"key":"2026090808100904000_51.9.1065.107","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200205000-00002"},{"key":"2026090808100904000_51.9.1065.108","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410200207"},{"key":"2026090808100904000_51.9.1065.109","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000177101.99398.22"},{"key":"2026090808100904000_51.9.1065.110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002856","article-title":"Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy","volume":"3","author":"Duarte","year":"2013","journal-title":"BMJ Open"},{"key":"2026090808100904000_51.9.1065.111","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/ner.12597","article-title":"Intrathecal Pump Refills, Pocket Fills, and Symptoms of Drug Overdose: A Prospective, Observational Study Comparing the Injected Drug Volume vs. the Drug Volume Effectively Measured Inside the Pump","volume":"20","author":"Maino","year":"2017","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.112","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/ner.12212","article-title":"The Accuracy of Template-Guided Refill Technique of Intrathecal Pumps Controlled by Fluoroscopy: An Observational Study","volume":"18","author":"Maino","year":"2015","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.113","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1526-4637.2011.01090.x","article-title":"Ultrasound-guided intrathecal pump access and prevention of the pocket fill","volume":"12","author":"Gofeld","year":"2011","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.114","doi-asserted-by":"publisher","DOI":"10.1097\/AAP.0000000000000008"},{"key":"2026090808100904000_51.9.1065.115","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/ner.12799","article-title":"Removal of Intrathecal Catheters Used in Drug Delivery Systems","volume":"21","author":"Frizon","year":"2018","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2015.12.340"},{"key":"2026090808100904000_51.9.1065.117","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/pm\/pnaf012","article-title":"Cancer patients quality of life after intrathecal drug delivery for advanced pain management: a patient-reported outcome analysis","volume":"26","author":"Goel","year":"2025","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.118","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.neurom.2022.03.003","article-title":"Effectiveness and Safety of Intrathecal Drug Delivery Systems for the Management of Cancer Pain: A Systematic Review and Meta-Analysis","volume":"26","author":"Duarte","year":"2023","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.119","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/20494637231202089","article-title":"Implanted intrathecal drug delivery systems may be associated with improved survival in patients with cancer","volume":"18","author":"Mitchell","year":"2024","journal-title":"Br J Pain"},{"key":"2026090808100904000_51.9.1065.120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003061","article-title":"Randomised, double-blind controlled trial by dose reduction of implanted intrathecal morphine delivery in chronic non-cancer pain","volume":"3","author":"Raphael","year":"2013","journal-title":"BMJ Open"},{"key":"2026090808100904000_51.9.1065.121","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/17434440.2022.2152673","article-title":"A post-market, randomized, controlled, prospective study evaluating intrathecal pain medication versus conventional medical management in the non-cancer, refractory, chronic pain population (PROSPER)","volume":"19","author":"Pope","year":"2022","journal-title":"Expert Rev Med Devices"},{"key":"2026090808100904000_51.9.1065.122","doi-asserted-by":"publisher","DOI":"10.1097\/ANA.0b013e31822ff779"},{"key":"2026090808100904000_51.9.1065.123","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/papr.12818","article-title":"Long-term Outcome and Adverse Events of Intrathecal Opioid Therapy for Nonmalignant Pain Syndrome","volume":"20","author":"Sommer","year":"2020","journal-title":"Pain Pract"},{"key":"2026090808100904000_51.9.1065.124","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.annfar.2013.02.021","article-title":"Guidelines for regional anesthetic and analgesic techniques in the treatment of chronic pain syndromes","volume":"32","author":"Beloeil","year":"2013","journal-title":"Ann Fr Anesth Reanim"},{"key":"2026090808100904000_51.9.1065.125","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1526-4637.2010.00841.x","article-title":"Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners","volume":"11","author":"Raphael","year":"2010","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.126","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00473.x"},{"key":"2026090808100904000_51.9.1065.127","unstructured":"La soci\u00e9t\u00e9 fran\u00e7aise d\u2019etude et traitement de la douleur (sfetd). Intrathecal toolkit; 2025. Available: https:\/\/sfetd-douleur.Org\/wp-content\/uploads\/2025\/01\/toolbox%20%2028012025.Pdf"},{"key":"2026090808100904000_51.9.1065.128","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.neurom.2023.02.080","article-title":"Symptomatic Intrathecal Catheter Tip Granuloma Formation With Ultralow-Dose and Low-Concentration Morphine Infusion: A Case Report and Review of Literature","volume":"26","author":"Gui","year":"2023","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.129","doi-asserted-by":"publisher","DOI":"10.1053\/rapm.2000.8574"},{"key":"2026090808100904000_51.9.1065.130","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1213\/00000539-198867110-00005","article-title":"Comparative motor-blocking effects of bupivacaine and ropivacaine, a new amino amide local anesthetic, in the rat and dog","volume":"67","author":"Feldman","year":"1988","journal-title":"Anesth Analg"},{"key":"2026090808100904000_51.9.1065.131","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/ner.13469","article-title":"First Evaluation Switching From Ropivacaine to Highly Concentrated Bupivacaine in Intrathecal Mixtures for Cancer Pain","volume":"24","author":"Bienfait","year":"2021","journal-title":"Neuromodulation"},{"key":"2026090808100904000_51.9.1065.132","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1526-4637.2002.02048.x","article-title":"Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data","volume":"3","author":"Yaksh","year":"2002","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.133","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1526-4637.2002.02014.x","article-title":"Intrathecal clonidine in the treatment of intractable pain: a phase I\/II study","volume":"3","author":"Hassenbusch","year":"2002","journal-title":"Pain Med"},{"key":"2026090808100904000_51.9.1065.134","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-030-81526-4_4","article-title":"Cancer Pain Management-A European Perspective","volume":"182","author":"Dupoiron","year":"2021","journal-title":"Cancer Treat Res"},{"key":"2026090808100904000_51.9.1065.135","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.neurom.2022.10.052","article-title":"A Clinical Evaluation of the Accuracy of an Intrathecal Drug Delivery Device","volume":"26","author":"Copley","year":"2023","journal-title":"Neuromodulation"}],"container-title":["Regional Anesthesia &amp; Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rapm-2025-107404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:24:27Z","timestamp":1788881067000},"score":1,"resource":{"primary":{"URL":"https:\/\/rapm.bmj.com\/lookup\/doi\/10.1136\/rapm-2025-107404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":135,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,8]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/rapm-2025-107404"],"URL":"https:\/\/doi.org\/10.1136\/rapm-2025-107404","relation":{},"ISSN":["1098-7339","1532-8651"],"issn-type":[{"value":"1098-7339","type":"print"},{"value":"1532-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}